Skip to main content
SpringerLink
Log in

Advance of prophylactic cranial irradiation in lung cancer

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Brain metastases in patients with lung cancer are a devastating problem with profound impact on survival. Prophylactic cranial irradiation has been discussed as an option to reduce the risk of brain metastases. This report provides an extensive review of the current evidence from non-randomized and randomized trials regarding the use of prophylactic cranial irradiation in lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol, 2005, 23: 6207–6219.

    Article  PubMed  CAS  Google Scholar 

  2. Kepka L, Cieslak E, Bujko K, et al. Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: the RTOG RPA intra-classes analysis. Acta Oncol, 2005, 44: 389–398.

    Article  PubMed  Google Scholar 

  3. Hochstenbag MM, Twijnstra A, Wilmink JT, et al. Asymptomatic brain metastases (BM) in small cell lung cancer (SCLC): MR-imaging is useful at initial diagnosis. J Neurooncol, 2000, 48: 243–248.

    Article  PubMed  CAS  Google Scholar 

  4. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst, 1995, 87: 183–190.

    Article  PubMed  CAS  Google Scholar 

  5. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med, 1999, 341: 476–484.

    Article  PubMed  Google Scholar 

  6. Castrucci WA, Knisely JP. An update on the treatment of CNS metastases in small cell lung cancer. Cancer J, 2008, 14: 138–146.

    Article  PubMed  Google Scholar 

  7. Le Péchoux C, Dunant A, Senan S, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limitedstage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol, 2009, 10: 467–474.

    Article  PubMed  Google Scholar 

  8. Wolfson AH, Bae K, Komaki R, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys, 2011, 81: 77–84.

    Article  PubMed  Google Scholar 

  9. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med, 2007, 357: 664–672.

    Article  PubMed  CAS  Google Scholar 

  10. Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III nonsmall-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol, 2005, 23: 2955–2961.

    Article  PubMed  Google Scholar 

  11. Carolana H, Suna AY, Bezjak A, et al. Does the incidence and outcome of brain metastases in locally advanced non-small cell lung cancer justify prophylactic cranial irradiation or early detection? Lung Cancer, 2005, 49: 109–115.

    Article  Google Scholar 

  12. Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol, 1995, 13: 1880–1892.

    PubMed  CAS  Google Scholar 

  13. Strauss GM, Herndon JE, Sherman DD, et al. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. J Clin Oncol, 1992, 10: 1237–1244.

    PubMed  CAS  Google Scholar 

  14. Skarin A, Jochelson M, Sheldon T, et al. Neoadjuvant chemotherapy in marginally resectable stage III M0 non-small cell lung cancer: longterm follow-up in 41 patients. J Surg Oncol, 1989, 40: 266–274.

    Article  PubMed  CAS  Google Scholar 

  15. Rusch VW, Griffin BR, Livingston RB. The role of prophylactic cranial irradiation in regionally advanced non-small cell lung cancer. A Southwest Oncology Group Study. J Thorac Cardiovasc Surg, 1989, 98: 535–539.

    PubMed  CAS  Google Scholar 

  16. Stuschke M, Eberhardt W, Pöttgen C, et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol, 1999, 17: 2700–2709.

    PubMed  CAS  Google Scholar 

  17. Cox JD, Stanley K, Petrovich Z, et al. Cranial irradiation in cancer of the lung of all cell types. JAMA, 1981, 245: 469–472.

    Article  PubMed  CAS  Google Scholar 

  18. Umsawasdi T, Valdivieso M, Chen TT, et al. Role of elective brain irradiation during combined chemoradiotherapy for limited disease non-small cell lung cancer. J Neurooncol, 1984, 2: 253–259.

    Article  PubMed  CAS  Google Scholar 

  19. Russell AH, Pajak TE, Selim HM, et al. Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys, 1991, 21: 637–643.

    Article  PubMed  CAS  Google Scholar 

  20. Mira JG, Miller TP, Crowley JJ, et al. Chest irradiation vs. chest irradiation plus chemotherapy with or without cranial prophylactic brain radiotherapy in localized non small cell lung cancer. A South West Oncology Group randomized study. Int J Radiat Oncol Biol Phys, 1990, 19: 145.

    Article  Google Scholar 

  21. Pöttgen C, Eberhardt W, Grannass A, et al. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol, 2007, 25: 4987–4992.

    Article  PubMed  Google Scholar 

  22. Gore EM, Bae K, Wong SJ, et al. Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol, 2011, 29: 272–278.

    Article  PubMed  Google Scholar 

  23. Wu YL. Prophylactic cranial irradiation (PCI) versus no PCI in non-small cell lung cancer after a pesponse to chemotherapy. Interner. (2008) Available: http://www.clinicaltrials.gov/ct2/show/NCT00745797?term=NCT00745797, August, 2012.

  24. Komaki R. Combined modality treatment for resectable non-small cell superiorsulcus tumors. Internet. (2011) Available: http://www.clinicaltrials.gov/ct2/show/NCT00984997?term=NCT00984997, August, 2012.

  25. Robnett TJ, Machtay M, Stevenson JP, et al. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol, 2001, 19: 1344–1349.

    PubMed  CAS  Google Scholar 

  26. Ceresoli GL, Reni M, Chiesa G, et al. Brain metastases in locally advanced non-small cell lung carcinoma after multimodality treatment: risk factors analysis. Cancer, 2002, 95: 605–612.

    Article  PubMed  Google Scholar 

  27. Keith B, Vincent M, Stitt L, et al. Subsets more likely to benefit from surgery or prophylactic cranial irradiation after chemoradiation for localized non-small cell lung cancer. Am J Clin Oncol, 2002, 25: 583–587.

    Article  PubMed  Google Scholar 

  28. Bajard A, Westeel V, Dubiez A, et al. Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma. Lung Cancer, 2004, 45: 317–323.

    Article  PubMed  CAS  Google Scholar 

  29. D’Amico TA, Aloia TA, Moore MB, et al. Predicting the sites of metastases from lung cancer using molecular biologic markers. Ann Thorac Surg, 2001, 72: 1144–1148.

    Article  PubMed  Google Scholar 

  30. Bubb RS, Komaki R, Hachiya T, et al. Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion. Int J Radiat Oncol Biol Phys, 2002, 53: 1216–1224.

    Article  PubMed  CAS  Google Scholar 

  31. Zhao JM, Zhu ZH, Su XD, et al. Clinical significance of Smac expression on non-small cell lung cancers. Chinese-German J Clin Oncol, 2011, 10: 249–251.

    Article  CAS  Google Scholar 

  32. Andre F, Grunenwald D, Pujol JL, et al. Patterns of relapse of N2 non-small-cell lung carcinoma patients treated with preoperative chemotherapy: should prophylactic cranial irradiation be reconsidered? Cancer, 2001, 91: 2394–2400.

    Article  PubMed  CAS  Google Scholar 

  33. Robnett TJ, Machtay M, Stevenson JP, et al. Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol, 2001, 19: 1344–1349.

    PubMed  CAS  Google Scholar 

  34. Ortuzar W, Hanna N, Pennella E, et al. Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer, 2012, 13: 24–30.

    Article  PubMed  CAS  Google Scholar 

  35. Ma SL, Xu YP, Deng QH, et al. Clinical features of gefitinib-responders with non-small cell lung cancer. J Clin Oncol, 2008, 26: 19136.

    Google Scholar 

  36. Omuro AM, Kris MG, Miller VA, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer, 2005, 103: 2344–2348.

    Article  PubMed  CAS  Google Scholar 

  37. Ma S, Xu Y, Deng Q, et al. Treatment of brain metastasis from nonsmall cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population. Lung Cancer, 2009, 65:198–203.

    Article  PubMed  Google Scholar 

  38. Xu Y, Ma S, Lin N, et al. Cerebrospinal fluid concentration of gefitinib in patients with central nervous system metastases of non-small cell lung cancer. J Thorac Oncol, 2011, 6: S39–1688.

    Article  Google Scholar 

  39. Gregor A, Cull A, Stephens RJ, et al. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European Organization for Research and Treatment of Cancer (EORTC). Eur J Cancer, 1997, 33: 1752–1758

    Article  PubMed  CAS  Google Scholar 

  40. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology, 1989, 39: 789–796

    Article  PubMed  CAS  Google Scholar 

  41. Abayomi OK. Pathogenesis of irradiationinduced cognitive dysfunction. Acta Oncol, 1996, 35: 659–663.

    Article  PubMed  CAS  Google Scholar 

  42. Monje ML, Mizumatsu S, Fike JR, et al. Irradiation induces neural precursor-cell dysfunction. Nat Med, 2002, 8: 955–962.

    Article  PubMed  CAS  Google Scholar 

  43. Gondi V, Tolakanahalli R, Mehta MP, et al. Hippocampal-sparing whole-brain radiotherapy: a “how-to” technique using helical tomotherapy and linear accelerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys, 2010, 78: 1244–1252.

    Article  PubMed  Google Scholar 

  44. Mira JG, Miller TP, Crowley JJ, et al. Chest irradiation (RT) vs chest RT+ chemotherapy ± prophylactic brain RT in localized non small cell lung cancer: a southwest oncology group randomized study. Int J Radiat Oncol Biol Phys, 1990, 19(suppl 1): 145.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, 310053, China

    Kan Wu

  2. Department of Radiation Oncology, Hangzhou First People’s Hospital, Hangzhou Cancer Hospital, Hangzhou, 310006, China

    Bing Xia & Shenglin Ma

Authors
  1. Kan Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bing Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shenglin Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shenglin Ma.

Additional information

Supported by grants from the Major Science and Technology Innovation Projects of Hangzhou (No. 20112313A01), the National Natural Science Foundation of China (No. 81172072), the Zhejiang Planning Project of Science and Technology (No. 2011F10015), and the Zhejiang Natural Science Foundation for Distinguished Young Scholars (No. R2101405).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, K., Xia, B. & Ma, S. Advance of prophylactic cranial irradiation in lung cancer. Chin. -Ger. J. Clin. Oncol. 11, 559–565 (2012). https://doi.org/10.1007/s10330-012-1048-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-012-1048-z

Key words

Search

Navigation